New drug tested for rare swelling disease
NCT ID NCT07025330
Summary
This study is testing if a drug called efgartigimod can reduce swelling in the tear glands, salivary glands, or pancreas in adults with IgG4-related disease. Up to 5 participants will receive weekly injections for 12 weeks and have regular checkups and scans. The goal is to see if the drug can control this rare inflammatory condition in people who haven't gotten enough benefit from steroid treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG4 RELATED DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304-2210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.